Investor Presentaiton slide image

Investor Presentaiton

sanofi First PCV21 pediatric vaccine extends protection against disease Serotype composition per vaccine IPD incremental coverage rate in all ages¹ 1 3 4 5 6A 6B 7F 9V 14 18C 19A 19F 23F 22F 33F 8 10A 11A 12F 15B 9N 2 17F 20 33F 8 10A1 Sanofi PCV21 Pfizer PCV20 Merck PCV15 Pfizer PCV13 27% NVT/Others 37% 5% PCV21 non PCV20 6% 31% PCV20 non PCV15 17% 14% 9% PCV15 non PCV13 26% 29% PCV13 non PCV10 US 2019+2020 EU 2019+2020 NVT: Non-vaccine type NT: Non-typable IPD: Invasive pneumococcal disease 1. All age groups - US ABC data and ECDC Surveillance Atlas 2. Internal model 3. Tiley KS, J Infect Dis 2022; Plainvert C, Infect Dis Now 2022; Ekinci E, Front in Pediatr 2021. 61 Vaccines Investor Event Significant residual burden in U.S. pediatrics < 5 years² ~1,500 cases IPD 1.5m Acute Otitis Media cases - 270k cases of pneumonia 9N serotype provides ~5-7% pts gain in IPD coverage across all ages1,3
View entire presentation